On 14 October 2016, orphan designation (EU/3/16/1760) was granted by the European Commission to Wainwright Associates Ltd, United Kingdom, for radio-iodinated (131I) anti-CD45 murine monoclonal antibody (also known as Iomab-B) for treatment in haematopoietic stem cell transplantation.
In November 2016, Wainwright Associates Ltd changed name to PharmaLex UK Services Limited.
The sponsorship was transferred to YES Pharmaceuticals Development Services GmbH, Germany, in April 2019.
Radio-iodinated (131I) anti-CD45 murine monoclonal antibody
|Disease / condition||
Treatment in haematopoietic stem cell transplantation
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;